drugset / Trial / NCT06455605
D2C7-IT + 2141-V11 Combination Post-resection in rGBM
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and efficacy of the combination of D2C7-IT+2141-V11 administered in the non-enhancing tumor of patients with resected recurrent glioblastoma (rGBM) via convection enhanced delivery (CED), followed by subcutaneous cervical perilymphatic injections (CPLIs) of 2141-V11 2 and 4 weeks post infusion, then every 3 weeks for a year, and every 4-6 weeks thereafter if patients benefit from therapy.
Timeline
- Start
- 2025-03-17
- Primary completion
- 2029-01-31
- Completion
- 2030-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 2141-V11 | Monoclonal antibody | 2 mg | Other |
| Subject | 2141-V11 | Monoclonal antibody | 3 mg | Other |
| Subject | D2C7-IT | Protein / enzyme biologic | 166075 ng | Other |